Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

1.

Parallel evolution of tumour subclones mimics diversity between tumours.

Martinez P, Birkbak NJ, Gerlinger M, McGranahan N, Burrell RA, Rowan AJ, Joshi T, Fisher R, Larkin J, Szallasi Z, Swanton C.

J Pathol. 2013 Aug;230(4):356-64. doi: 10.1002/path.4214.

PMID:
23716380
[PubMed - indexed for MEDLINE]
2.

Genetic and epigenetic alterations during renal carcinogenesis.

Arai E, Kanai Y.

Int J Clin Exp Pathol. 2010 Dec 13;4(1):58-73. Review.

PMID:
21228928
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Potential role of genetic markers in the management of kidney cancer.

Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, Oosterwijk E.

Eur Urol. 2013 Feb;63(2):333-40. doi: 10.1016/j.eururo.2012.09.040. Epub 2012 Sep 24. Review.

PMID:
23040205
[PubMed - indexed for MEDLINE]
4.

Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.

Audenet F, Yates DR, Cancel-Tassin G, Cussenot O, Rouprêt M.

BJU Int. 2012 Jun;109(12):1864-70. doi: 10.1111/j.1464-410X.2011.10661.x. Epub 2011 Oct 28. Review.

PMID:
22035299
[PubMed - indexed for MEDLINE]
5.

The role of molecular markers in the staging of renal cell carcinoma.

Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS.

BJU Int. 2007 May;99(5 Pt B):1208-11. Review. No abstract available.

PMID:
17441912
[PubMed - indexed for MEDLINE]
6.

From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Arsanious A, Bjarnason GA, Yousef GM.

Mol Cancer. 2009 Mar 17;8:20. doi: 10.1186/1476-4598-8-20. Review.

PMID:
19291329
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Rationale for percutaneous biopsy and histologic characterisation of renal tumours.

Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ, Remzi M, Uzzo RG.

Eur Urol. 2012 Sep;62(3):491-504. doi: 10.1016/j.eururo.2012.05.009. Epub 2012 May 12. Review.

PMID:
22633318
[PubMed - indexed for MEDLINE]
8.

Advances in molecular classification of renal neoplasms.

Yin-Goen Q, Dale J, Yang WL, Phan J, Moffitt R, Petros JA, Datta MW, Amin MB, Wang MD, Young AN.

Histol Histopathol. 2006 Mar;21(3):325-39. Review.

PMID:
16372253
[PubMed - indexed for MEDLINE]
9.

Prognostic markers in renal cell carcinoma.

Ljungberg B.

Curr Opin Urol. 2007 Sep;17(5):303-8. Review.

PMID:
17762621
[PubMed - indexed for MEDLINE]
10.

The value of molecular genetic analysis in the diagnosis and prognosis of renal cell tumours.

Kovacs G.

World J Urol. 1994;12(2):64-8. Review.

PMID:
8087142
[PubMed - indexed for MEDLINE]
11.

[Hippel-Lindau syndrome and sporadic renal cell carcinomas. Pathogenesis, morphologic spectrum and molecular genetics].

Brauch H, Böhm J, Höfler H.

Pathologe. 1995 Sep;16(5):321-7. Review. German.

PMID:
7479604
[PubMed - indexed for MEDLINE]
12.

The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.

Wyatt AW, Mo F, Wang Y, Collins CC.

Asian J Androl. 2013 May;15(3):301-8. doi: 10.1038/aja.2013.13. Epub 2013 Mar 18. Review.

PMID:
23503423
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Adapting clinical paradigms to the challenges of cancer clonal evolution.

Murugaesu N, Chew SK, Swanton C.

Am J Pathol. 2013 Jun;182(6):1962-71. doi: 10.1016/j.ajpath.2013.02.026. Review.

PMID:
23708210
[PubMed - indexed for MEDLINE]
Free Article
14.

The causes and consequences of genetic heterogeneity in cancer evolution.

Burrell RA, McGranahan N, Bartek J, Swanton C.

Nature. 2013 Sep 19;501(7467):338-45. doi: 10.1038/nature12625. Review.

PMID:
24048066
[PubMed - indexed for MEDLINE]
15.

Extracellular vesicles as prospective carriers of oncogenic protein signatures in adult and paediatric brain tumours.

Garnier D, Jabado N, Rak J.

Proteomics. 2013 May;13(10-11):1595-607. doi: 10.1002/pmic.201200360. Epub 2013 Apr 20. Review.

PMID:
23505048
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk